Review articleAnalyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis
Section snippets
History and general considerations
In late nineteenth century, Heinrich Irenaϋs Quincke and Heinrich Georg Queckenstedt developed methods of sampling and studying cerebrospinal fluid (CSF) (Murray, 2005). CSF sampling was initially developed for therapeutic purposes in the treatment of hydrocephalus, but shortly became a very useful diagnostic test for infections and other disorders.
The first to report a CSF abnormality in multiple sclerosis (MS) was Hinton (1922), when he noticed that patients with MS and syphilis had an
Oligoclonal banding: current methodology
AGE and IEF are two methodologies currently employed for the detection of CSF OCBs. The sensitivity of AGE for the detection of OCBs in MS CSF varies from 47% to 77% (Luque and Jaffe, 2007a). Paired CSF and serum are electrophoresed on high-resolution agarose and stained for protein to identify unique CSF protein bands in the γ region. A positive test is considered 2 or more bands in the γ region of the CSF that do not appear in the serum. Unfortunately, considerable inconsistencies in
Oligoclonal bands in multiple sclerosis: roles in diagnosis, prognosis, and monitoring of disease activity
The diagnosis of MS is ultimately a clinical decision that does not require laboratory tests if neurologic dysfunction in time and space can be established, and alternative diagnoses excluded. However, CSF analysis is extremely helpful in patients with an atypical clinical presentation, age of onset, or magnetic resonance imaging (MRI) (Merra, 1984). It is also of paramount importance to exclude some infectious and inflammatory mimics (Herndon, 2006). For this particular purpose, CSF studies
Additional CSF measures in multiple sclerosis
The IgG index (CSF/serum IgG:CSF/serum albumin) is elevated (> 0.6) in about 70%–90% of MS patients but is rarely abnormal in OCBs-negative patients. Due to its relatively low sensitivity, the IgG index cannot replace testing for OCBs, but an isolated elevated IgG index should arouse clinical suspicion for demyelinating disease in the appropriate clinical context (Reiber et al., 1998, Tourtellotte et al., 1976, McLean et al., 1990). The IgG index, however, may have a value in therapeutic
The effect of pharmacotherapies on the presence of oligoclonal bands in patients with MS
There is currently unsufficient evidence that any of the approved pharmacotherapies for MS has a biologically relevant bioavailability in the CNS compartment. Furthermore, it is currently uncertain to what degree these agents have indirect effects on humoral immune responses within the brain and spinal cord. The immunomodulatory agent interferon beta has no apparent effect on the number of OCBs in the CSF (Confavreux et al., 1986, Rudick et al., 1999b). For glatiramer acetate, there is no data
CSF studies in patients with a clinically isolated syndrome
CSF parameters may play an important role in predicting the development of clinically definitive MS (CDMS) in patients with a clinically isolated syndrome (CIS), which may ultimately lead to earlier and more effective therapeutic interventions for these individuals. In the early 1980s, Poser et al. (1982) demonstrated that the presence of OCBs is positively correlated with development of CDMS in isolated myelitis. In a group of 52 patients with CIS, confirming the presence of OCBs by IEF was
Novel potential CSF biomarkers in MS
In clinical practice, only OCBs and IgG index are routinely utilized. Nevertheless, a very large number of markers are under investigation and may prove helpful in a variety of clinical settings. A list of potential CSF biomarkers is shown in Table 2 (Matsuda et al., 1995, Droogan et al., 1996, Mössner et al., 1996, McDonnell et al., 1998, Frigerio et al., 1998, Baraczka et al., 1999, Baraczka et al., 2001, Baraczka et al., 2003, McMillan et al., 2000, Rieckmann et al., 1998, Correale and
Summary
The role of CSF examination in MS diagnosis and the determination of prognosis are in constant flux. Currently, its main role is to support and rule-out the diagnosis of MS, and to exclude differential diagnoses. However, new technologies may expand to the role of paraclinical CSF testing in the future. It is conceivable that CSF biomarkers, alone or in addition with other surrogate disease markers on MRI, may help the clinician to predict disease progression from CIS to CDMS, and to monitor
References (126)
- et al.
CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome
J. Neuroimmunol.
(2008) - et al.
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis
J. Neuroimmunol.
(2009) - et al.
Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS
J. Neuroimmunol.
(2003) - et al.
Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients
J. Neuroimmunol.
(2006) - et al.
Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1
J. Neuroimmunol.
(1996) - et al.
Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients
J. Neuroimmunol.
(1998) - et al.
Changes in human plasma levels of brain specific oxysterol 24S-hydroxycholestrol during progression of multiple sclerosis
Neurosci. Lett.
(2002) - et al.
Levels of 7-oxocholesterol in cerebrospinal fluid are more than one thousand times lower than reported in multiple sclerosis
J. Lipid Res.
(2005) - et al.
Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness
J. Neuroimmunol.
(2006) - et al.
Cerebrospinal fluid analysis in multiple sclerosis
Int. Rev. Neurobiol.
(2007)
Cerebrospinal fluid analysis in multiple sclerosis
Int. Rev. Neurobiol.
Virus-specific and autoreactive T cell lines isolated from cerebrospinal fluid of a patient with chronic rubella panencephalitis
J. Neuroimmunol.
Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy
J. Neuroimmunol.
Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis
J. Neuroimmunol.
Absence of oligoclonal IgA in CSF and serum of multiple sclerosis patients
J. Neuroimmunol.
Symptomatic female heterozygous for adrenoleukodystrophy: a report of two unrelated cases and review of the literature
J. Clin. Neurosci.
An improved formula for judgment of intrathecally produced IgG in the presence of blood brain barrier damage
Clin. Chim. Acta
Protein transfer at the blood cerebrospinal fluid barrier and quantification of humoral immune response within central nervous system
Clin. Chem. Acta
Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit
J. Neurol. Sci.
Cerebrospinal fluid abnormalities in phase III trial of Avonex (IFN-beta-1a) for relapsing multiple sclerosis
J. Neuroimmunol.
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis
J. Neuroimmunol.
Intrathecal sICAM-1 production in multiple sclerosis—correlation with triple dose Gd-DTPA MRI enhancement and IgG index
J. Neurol.
Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: a preliminary study
J. Neuroinflammation
Immunoenzymatic determination of free immunoglobulin light chains in the cerebrospinal fluid: its value in the biological diagnosis of multiple sclerosis
Arch. Inst. Pasteur Algerie
Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report
J. Neurol. Neurosurg. Psychiatry
A study of increased levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) in the cerebrospinal fluid of patients with multiple sclerosis and systemic lupus erythematosus
Acta Neurol. Scand.
Soluble L-selectin levels in serum and cerebrospinal fluid in patients with multiple sclerosis and systemic lupus erythematosus
Acta Neurol. Scand.
Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement
Neuroimmunomodulation
Increased levels of tumor necrosis alpha and soluble vascular endothelial adhesion molecule-1 in the cerebrospinal fluid of patients with connective tissue diseases and multiple sclerosis
Acta Microbiol. Immunol. Hung.
Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients
J. Neural Transm.
Cerebrospinal-fluid profile in neuroborreliosis and its diagnostic significance
Folia Microbiol. (Praha)
Antimyelin antibodies as a predictor of clinically definitive multiple sclerosis after a first demyelinating event
N. Engl. J. Med.
Free light chains in the CSF in multiple sclerosis
J. Neurol.
Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis
Mult. Scler.
Diagnosis and biological monitoring of 6 neurosyphilis cases: value of cerebrospinal fluid analysis
Ann. Biol. Clin. (Paris)
Cerebrospinal fluid oligoclonal IgG bands in patients with spinal arteriovenous malformation and structural central nervous system lesions
Arch. Neurol.
Oligoclonal “fingerprint” of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon
J. Neurol. Neurosurg. Psychiatry
Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force
Eur. J. Neurol.
Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients
Medicine (Baltimore)
Findings of cerebrospinal fluid in the diagnosis of multiple sclerosis
Srp. Arh. Celok. Lek.
Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy
Neurology
Cerebrospinal fluid oliogoclonal bands in the diagnosis of multiple sclerosis
Am. J. Clin. Pathol.
Measurement of IgG and albumin quotients of cerebrospinal fluid and its interpretation
Clin. Chem.
Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment
Eur. J. Neurol.
Cerebrospinal fluid analysis in human immunodeficiency virus infection
Ann. Clin. Lab. Sci.
B-lymphocyte and plasma cell clonal expansion in monosymptomatic optic neuritis cerebrospinal fluid
Ann. Neurol.
Multiple sclerosis mimics
Adv. Neurol.
CSF in MS
Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients
Arch. Neurol.
Cited by (74)
Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to “overlap” cases
2022, Journal of NeuroimmunologyMultiple sclerosis with intractable vomiting and atypical area postrema lesion
2020, Multiple Sclerosis and Related DisordersBioluminescent aptamer-based sandwich-type assay of anti-myelin basic protein autoantibodies associated with multiple sclerosis
2019, Analytica Chimica ActaCitation Excerpt :Early diagnostics and timely treatment may decelerate the disease progression and improve patient life. At the same time, verification of MS diagnosis requires a combination of diagnostic tests, including magnetic resonance imaging (MRI) and cerebrospinal fluid analysis [4], which are expensive, time-consuming and fraught with adverse effects. Thereby, the identification of biomarkers strongly associated with MS and the development of diagnostic assays is a significant unmet need for assessing disease prognosis, response to therapy, or potential treatment complications [5,6].
Validation and meta-analysis of kappa index biomarker in multiple sclerosis diagnosis
2019, Autoimmunity ReviewsCitation Excerpt :Unfortunately, IgG index has a low sensitivity, so it cannot replace the diagnostic value of OCGB. Nevertheless, its quantification is indispensable for performing the OCGB technique properly [6]. In the search for alternative biomarkers with high MS diagnostic and prognostic power, free light chains (FLC) in CSF have been determined.
Multiple Sclerosis
2016, International Encyclopedia of Public Health